Pharmacological activation of wild-type p53 has been found to protect normal cells in culture
from cytotoxicity and nuclear aberrations caused by conventional cancer therapeutics …

Mutations in the tumor suppressor gene TP5 3 represent the most frequent genetic
difference between tumor cells and normal cells. Here, we have attempted to turn this …

The activation of p53 has been proposed as a novel anti-cancer treatment in two distinct
contexts. In the first activation of p53 in tumor cells can promote apoptosis and senescence …

Cancer cells are generally more sensitive to anticancer drugs than normal cells. This
provides the rationale for using anticancer drugs specifically against tumor cells, but the …

Side effects of chemotherapy are a major impediment in the treatment of cancer.
Cyclotherapy is an emerging therapeutic strategy for protecting normal cells from the side …

Carcinogenesis is a multistage process, involving oncogene activation and tumor
suppressor gene inactivation as well as complex interactions between tumor and host …

The p53 tumor suppressor pathway is a key mediator of stress response that protects the
organism from accumulating genetically altered and potentially cancerous cells by inducing …

Tumor suppressor p53 is a transcription factor that regulates a large number of genes and
guards against genomic instability. Under multiple cellular stress conditions, p53 functions to …

Inactivation of p53 functions is an almost universal feature of human cancer cells. This has
spurred a tremendous effort to develop p53 based cancer therapies. Gene therapy using …

Recent studies have shown that activation of cell cycle checkpoints can protect normal
proliferating cells from mitotic inhibitors by preventing their entry into mitosis. These studies …